Dipeptidyl Peptidase - 4 Inhibitors - An Overview of the Combination of These Molecules and Hypoglicemic Oral Drugs
Cristina Iancu
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Oana Cioancă
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Madalina Mocanu
Department of Oromaxillofacial and Dentoalveolar Surgery, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Flavia Burlec
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Andreea Corciovă
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Nina Filip *
Department of Morphofunctional Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Monica Hăncianu
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
Cornelia Mircea
Department of Pharmaceutical Sciences II, ”Grigore T. Popa” University of Medicine and Pharmacy, Iași, România.
*Author to whom correspondence should be addressed.
Abstract
The purpose of the current review is to bring up to date some studies and data about the effects of hypoglycemic oral drugs in combination with DPP-4 inhibitors. As the medicine and pharmaceutical industry are revolutionary in type 2 diabetes protocols, scientists made a close research on patients that have combined metformin plus sulfonyurea and metformin plus DPP-4 inhibitors. Statistics showed that sulfonylurea compared to DPP-4 inhibitors, in combination with metformin, increased the risk of severe hypoglycemia, fatal and nonfatal cardiovascular diseases, and mortality. Another important discovery showed that the insulin associated with metformin increased the risk of all-caused mortality, compared with the DPP-4 inhibitors plus metformin.
Keywords: Dipeptidyl peptidase - 4 inhibitor, type 2 diabetes, oral drugs